Volta Medical's RESTART Trial Shows Promising Findings for AI Solutions in Recurrent Atrial Fibrillation

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Volta-Medical-RESTART

More Like This

PR Newswire associated0

Volta Medical Appoints Bill Hoffman as Executive Chairman of the Board of Directors

A New Hope for Atrial Fibrillation Patients with Breakthrough Catheter Technology

PR Newswire associated0

New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib

PR Newswire associated0

Circulation Publishes 6-Month Outcomes from First-in-Human VCAS Trial of FieldForce™ Pulsed Field Ablation System: 82% Freedom from VT/VF Recurrence and 98% Reduction in Burden

PR Newswire associated0

Biosense Webster Announces CE Mark approval in Europe for VARIPULSE™ Pulsed Field Ablation (PFA) Platform

PR Newswire associated0

Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

PR Newswire associated0

Lucem Health Introduces Reveal for Stroke to Accelerate Treatment of AFib-Related Stroke Risks

PR Newswire associated0

AuriGen Medical Pioneers Next-Generation Atrial Fibrillation Technology with First-in-Human Success